Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.

Johnson & Johnson is an impeccable dividend stock with a streak of 63 consecutive dividend raises. The company's long history ...

Like a lot of people, I’d had some squamous cell carcinomas removed from my scalp. But in June, 2024, a red splotch, about the size of my fist, appeared on ...

Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, ...

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...

The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the ...

MSD has received US Food and Drug Administration (FDA) approval for its anti-programmed death receptor-1 (PD-1) therapy, ...

Merck ( MRK) is a global biopharmaceutical giant with a diversified portfolio that spans across oncology, vaccines, ...

The Dow Jones Industrial Average ( ^DJI -1.79%) index edged 3.9% higher in May, with 70% of its 30 constituent stocks ending the month in positive territory. However, the two worst-performing Dow ...

Keytruda was approved for locally advanced head and neck cancer before and after surgery, showing improved event-free ...

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE ...